About: Proteolix     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:SocialGroup107950920, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FProteolix

Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California. Proteolix was founded in 2003 based on technology developed by co-founders Dr. Craig Crews (Yale University) and Dr. Raymond J. Deshaies (California Institute of Technology). Drs. Susan Molineaux and Phil Whitcome (deceased) joined Drs. Crews and Deshaies as co-founders. Proteolix was launched based on an $18.2 million A round comprising investments by Latterell Venture Partners, US Venture Partners, Advanced Technology Ventures, and The Vertical Group. Proteolix focused primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide . At the time of its sale (see below), the company had two earlier-stage programs, an orally-bio

AttributesValues
rdf:type
rdfs:label
  • Proteolix (en)
rdfs:comment
  • Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California. Proteolix was founded in 2003 based on technology developed by co-founders Dr. Craig Crews (Yale University) and Dr. Raymond J. Deshaies (California Institute of Technology). Drs. Susan Molineaux and Phil Whitcome (deceased) joined Drs. Crews and Deshaies as co-founders. Proteolix was launched based on an $18.2 million A round comprising investments by Latterell Venture Partners, US Venture Partners, Advanced Technology Ventures, and The Vertical Group. Proteolix focused primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide . At the time of its sale (see below), the company had two earlier-stage programs, an orally-bio (en)
foaf:name
  • Proteolix, Inc. (en)
name
  • Proteolix, Inc. (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
founder
  • (en)
  • Craig M. Crews (en)
  • Raymond J. Deshaies (en)
  • Drs. Crews and Deshaies (en)
  • Drs. Susan Molineaux (en)
  • Phil Whitcome (en)
hq location
type
  • Private biotechnology company (en)
has abstract
  • Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California. Proteolix was founded in 2003 based on technology developed by co-founders Dr. Craig Crews (Yale University) and Dr. Raymond J. Deshaies (California Institute of Technology). Drs. Susan Molineaux and Phil Whitcome (deceased) joined Drs. Crews and Deshaies as co-founders. Proteolix was launched based on an $18.2 million A round comprising investments by Latterell Venture Partners, US Venture Partners, Advanced Technology Ventures, and The Vertical Group. Proteolix focused primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide . At the time of its sale (see below), the company had two earlier-stage programs, an orally-bioavailable proteasome inhibitor for oncology (PR-047), and an agent preferentially targeting the immuno form of the proteasome (PR-957), with potential utility in areas such as rheumatoid arthritis. At the time of sale, Carfilzomib's route of administration was intravenous, and the company was exploring its potential utility in multiple myeloma, Non-Hodgkin lymphoma (NHL) and other cancers. Proteolix was acquired by Onyx Pharmaceuticals in 2009 for $810 million (nominal value). Onyx renamed PR-047 to "ONX 0912" and PR-957 to "ONX 0914". (en)
prov:wasDerivedFrom
page length (characters) of wiki page
founding year
founded by
headquarter
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is known for of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 59 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software